Emerging Markets Earnings Roundup: Johnson & Johnson (Part 1)
This article was originally published in PharmAsia News
Executive Summary
Third quarter earnings news from Johnson & Johnson was slim on emerging markets insight, but the company’s views on a possible Remicade challenge from Celltrion in the United States came across loud and clear.